SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
(X) Quarterly report for the quarterly period ended December 31, 1997
OR
( ) Transition Report Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Commission file number 1-9601
K-V PHARMACEUTICAL COMPANY
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 43-0618919
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
2503 SOUTH HANLEY ROAD, ST. LOUIS, MISSOURI 63144
- --------------------------------------------------------------------------------
(Address or principal executive offices)
(Zip Code)
(314) 645-6600
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or such shorter period that the registrant
was required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
Title of Class of Number of Shares
Common Stock Outstanding as of this Report Date
Class A Common Stock, par value $.01 per share 7,774,177
------------------
Class B Common Stock, par value $.01 per share 4,296,150
------------------
<PAGE>
Item 6: Exhibits and Reports on Form 8-K.
(a) Exhibits
Exhibit 27.
(b) The Company did not file any reports on Form 8-K during the quarter
ended December 31, 1997.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KV PHARMACEUTICAL COMPANY
Date: February 17, 1998 /s/ Marc S. Hermelin
--------------------------- --------------------
Marc S. Hermelin
Vice Chairman of the Board
Date: February 17, 1998 /s/ Gerald R. Mitchell
------------------------------- ----------------------
Gerald R. Mitchell
Vice President - Finance
Chief Financial Officer
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND> This schedule contains summary financial information
extracted from the Company's Balance Sheet at December 31, 1997 and the
Company's Statement of Income for the Nine Months Ended December 31, 1997 and is
qualified in its entirety by reference to such financial statements.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> MAR-31-1998
<PERIOD-START> APR-01-1997
<PERIOD-END> DEC-31-1997
<CASH> 9,378,460
<SECURITIES> 0
<RECEIVABLES> 16,897,249
<ALLOWANCES> 0
<INVENTORY> 16,446,844
<CURRENT-ASSETS> 44,295,219
<PP&E> 12,254,501
<DEPRECIATION> 0
<TOTAL-ASSETS> 59,910,380
<CURRENT-LIABILITIES> 14,073,048
<BONDS> 0
0
2,410
<COMMON> 121,178
<OTHER-SE> 0
<TOTAL-LIABILITY-AND-EQUITY> 59,910,380
<SALES> 68,525,787
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 39,590,928
<OTHER-EXPENSES> 18,259,917
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 327,885
<INCOME-PRETAX> 10,347,057
<INCOME-TAX> 3,560,672
<INCOME-CONTINUING> 6,786,385
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 6,786,385
<EPS-PRIMARY> .54
<EPS-DILUTED> .52
</TABLE>
